ENTI yields 20000000.00% · ABBV yields 3.06%● Live data
📍 ENTI pulled ahead of the other in Year 1
Combined, ENTI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENTI + ABBV for your $10,000?
Encounter Development Technologies Inc. operates as an online video distribution and technology company that launches proprietary syndication platforms and offers a range of video technology and distribution services to other companies. The company develops and programs solutions for the online streaming, distribution, and networking, as well as for the social network and distribution platforms. It also offers end-to-end technology and online marketing services, including design, build, hosting, and online marketing support. The company primarily operates GlobalAdOn.com, a patented technology for the yellow pages publishing industry. Its sales and management platform facilitates the sales and video production process for Internet yellow page publishers and their sales forces, as well as integrates and facilitates various processes, such as video shoot, sales rep, and publisher. The company was formerly known as Encounter Technologies, Inc. and changed its name to Encounter Development Technologies, Inc. in September 2011. Encounter Development Technologies Inc. was founded in 1986 and is based in Las Vegas, Nevada.
Full ENTI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.